{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:49:37Z","timestamp":1790012977577,"version":"4.0.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,7]]},"DOI":"10.7759\/cureus.98655","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T01:03:41Z","timestamp":1765155821000},"source":"Crossref","is-referenced-by-count":1,"title":["Understanding Treatment Completion and Tolerability of Intravesical Bacillus Calmette-Gu\u00e9rin (BCG) for Non-muscle Invasive Bladder Cancer in a Single UK Health Board"],"prefix":"10.7759","author":[{"given":"Sami","family":"Mohammed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Aniah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chalint","family":"Saougki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed E","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie E","family":"Badawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badreldin","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaza","family":"Faycal Mirghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdolazeem","family":"Elnour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.40962","article-title":"The management of Bacillus Calmette-Gu\u00e9rin (BCG) failure in high-risk non-muscle invasive bladder cancer: a review article","volume":"15","author":"Kodera A","year":"2023","unstructured":"Kodera A, Mohammed M, Lim P, Abdalla O, Elhadi M. The management of Bacillus Calmette-Gu\u00e9rin (BCG) failure in high-risk non-muscle invasive bladder cancer: a review article. Cureus. 2023, 15:e40962. 10.7759\/cureus.40962","journal-title":"Cureus"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) - 2019 update","volume":"76","author":"Babjuk M","year":"2019","unstructured":"Babjuk M, Burger M, Comp\u00e9rat EM, et al.. European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) - 2019 update. Eur Urol. 2019, 76:639-57. 10.1016\/j.eururo.2019.08.016","journal-title":"Eur Urol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.acuro.2020.08.003","article-title":"Current treatments for BCG failure in non-muscle invasive bladder cancer (NMIBC)","volume":"45","author":"\u00c1lvarez-Maestro M","year":"2021","unstructured":"\u00c1lvarez-Maestro M, Guerrero-Ramos F, Rodr\u00edguez-Faba O, Dom\u00ednguez-Escrig JL, Fern\u00e1ndez-G\u00f3mez JM. Current treatments for BCG failure in non-muscle invasive bladder cancer (NMIBC). Actas Urol Esp (Engl Ed). 2021, 45:93-102. 10.1016\/j.acuro.2020.08.003","journal-title":"Actas Urol Esp (Engl Ed)"},{"key":"ref4","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. (2017). https.\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/ans.70281","article-title":"BCG intolerance in nonmuscle invasive bladder cancer-a systematic review","author":"Oh C","year":"2025","unstructured":"Oh C, Bourlotos G, O'Callaghan M, Grundy L, Hong M. BCG intolerance in nonmuscle invasive bladder cancer-a systematic review. ANZ J Surg. 2025, 10.1111\/ans.70281","journal-title":"ANZ J Surg"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-025-01734-6","article-title":"Factors predicting local or systemic side effects related to intravesical BCG (Bacillus Calmette-Gu\u00e9rin) therapy: a retrospective observational study","volume":"25","author":"Aksakalli T","year":"2025","unstructured":"Aksakalli T, Utlu A, Celik F, Cinislioglu AE, Demirdogen SO, Atar M, Karabulut I. Factors predicting local or systemic side effects related to intravesical BCG (Bacillus Calmette-Gu\u00e9rin) therapy: a retrospective observational study. BMC Urol. 2025, 25:49. 10.1186\/s12894-025-01734-6","journal-title":"BMC Urol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2022.05.016","article-title":"Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer","volume":"40","author":"Ferro M","year":"2022","unstructured":"Ferro M, Barone B, Crocetto F, et al.. Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer. Urol Oncol. 2022, 40:490.e13-20. 10.1016\/j.urolonc.2022.05.016","journal-title":"Urol Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4103\/UA.UA_137_19","article-title":"Single course of intravesical Bacillus Calmette-Guerin versus single course with maintenance therapy in the management of nonmuscle invasive bladder cancer: a prospective randomized study","volume":"12","author":"Mohamed MB","year":"2020","unstructured":"Mohamed MB, Ali MH, Shamaa MA, Shaaban SM. Single course of intravesical Bacillus Calmette-Guerin versus single course with maintenance therapy in the management of nonmuscle invasive bladder cancer: a prospective randomized study. Urol Ann. 2020, 12:360-5. 10.4103\/UA.UA_137_19","journal-title":"Urol Ann"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0273733","article-title":"Effects of intravesical BCG maintenance therapy duration on recurrence rate in high-risk non-muscle invasive bladder cancer (NMIBC): systematic review and network meta-analysis according to EAU COVID-19 recommendations","volume":"17","author":"Moon YJ","year":"2022","unstructured":"Moon YJ, Cho KS, Jeong JY, Chung DY, Kang DH, Jung HD, Lee JY. Effects of intravesical BCG maintenance therapy duration on recurrence rate in high-risk non-muscle invasive bladder cancer (NMIBC): systematic review and network meta-analysis according to EAU COVID-19 recommendations. PLoS One. 2022, 17:e0273733. 10.1371\/journal.pone.0273733","journal-title":"PLoS One"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2020.06.013","article-title":"Low compliance to guidelines in nonmuscle-invasive bladder carcinoma: a systematic review","volume":"38","author":"Mori K","year":"2020","unstructured":"Mori K, Miura N, Babjuk M, et al.. Low compliance to guidelines in nonmuscle-invasive bladder carcinoma: a systematic review. Urol Oncol. 2020, 38:774-82. 10.1016\/j.urolonc.2020.06.013","journal-title":"Urol Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.3143","article-title":"Low compliance with guidelines for re-staging in high-grade T1 bladder cancer and the potential impact on patient outcomes in the province of Alberta","volume":"10","author":"Gotto GT","year":"2016","unstructured":"Gotto GT, Shea-Budgell MA, Dean Ruether J. Low compliance with guidelines for re-staging in high-grade T1 bladder cancer and the potential impact on patient outcomes in the province of Alberta. Can Urol Assoc J. 2016, 10:33-8. 10.5489\/cuaj.3143","journal-title":"Can Urol Assoc J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/442811-understanding-treatment-completion-and-tolerability-of-intravesical-bacillus-calmette-gurin-bcg-for-non-muscle-invasive-bladder-cancer-in-a-single-uk-health-board","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T01:03:49Z","timestamp":1765155829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/442811-understanding-treatment-completion-and-tolerability-of-intravesical-bacillus-calmette-gurin-bcg-for-non-muscle-invasive-bladder-cancer-in-a-single-uk-health-board"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,7]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.98655","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,7]]}}}